Inclusion Criteria:

- Histologically confirmed malignant solid tumor for which there are no known regimens
or protocol treatments of higher efficacy or priority

- Failed conventional therapy for the cancer or have a malignancy for which a
conventional therapy does not exist

- Recovered from all acute adverse effects of prior therapies, excluding alopecia (hair
loss)

- Life expectancy of at least 12 weeks and an EOCG performance status of 0 or 1

- 18 years of age or older

- Adequate kidney, liver, and bone marrow function

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or
mitomycin C) prior to entering the study or have not recovered from adverse effects
due to agents administered more than 4 weeks earlier

- Receiving any other investigational agent

- History of brain metastases or spinal cord compression, unless irradiated a minimum
of 4 weeks before study entry and stable without requirement for corticosteroids for
> 1 week

- History of allergic reactions attributed to compounds of similar chemical composition
to NK012

- Concurrent serious infections (i.e., requiring an intravenous antibiotic)

- Pregnant women or women of childbearing potential who are not using methods to avoid
pregnancy; a negative pregnancy test (urine or serum) must be documented at baseline
and before every NK012 administration for women of childbearing potential; no
breast-feeding while on study

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, unstable angina pectoris or psychiatric illness/social situations that
would limit compliance with study requirements

- Significant cardiac disease

- History of serious ventricular arrhythmia

- Positive for anti-HbsAg, anti-HCV, anti-HIV, or anti-syphilis antibodies